As combination therapy could augment different cell types to improve anti-tumor immunity, we characterized CD8+, Tconv (CD4+Foxp3−), Tregs (CD4+Foxp3+), DCs (CD11c+MHC-II+), monocytic (CD11b+Ly6C+/−F480+/−CD64+/−) and neutrophilic (CD11b+Ly6G+) derived myeloid cell populations (online supplemental figure S8C). This evidence concerns the gene CD4 and neoplasm.